Literature DB >> 19446321

DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival.

Timothy R Peterson1, Mathieu Laplante, Carson C Thoreen, Yasemin Sancak, Seong A Kang, W Michael Kuehl, Nathanael S Gray, David M Sabatini.   

Abstract

The mTORC1 and mTORC2 pathways regulate cell growth, proliferation, and survival. We identify DEPTOR as an mTOR-interacting protein whose expression is negatively regulated by mTORC1 and mTORC2. Loss of DEPTOR activates S6K1, Akt, and SGK1, promotes cell growth and survival, and activates mTORC1 and mTORC2 kinase activities. DEPTOR overexpression suppresses S6K1 but, by relieving feedback inhibition from mTORC1 to PI3K signaling, activates Akt. Consistent with many human cancers having activated mTORC1 and mTORC2 pathways, DEPTOR expression is low in most cancers. Surprisingly, DEPTOR is highly overexpressed in a subset of multiple myelomas harboring cyclin D1/D3 or c-MAF/MAFB translocations. In these cells, high DEPTOR expression is necessary to maintain PI3K and Akt activation and a reduction in DEPTOR levels leads to apoptosis. Thus, we identify a novel mTOR-interacting protein whose deregulated overexpression in multiple myeloma cells represents a mechanism for activating PI3K/Akt signaling and promoting cell survival.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19446321      PMCID: PMC2758791          DOI: 10.1016/j.cell.2009.03.046

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  49 in total

Review 1.  PDZ domains: folding and binding.

Authors:  Per Jemth; Stefano Gianni
Journal:  Biochemistry       Date:  2007-07-10       Impact factor: 3.162

2.  Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation.

Authors:  Andrew Y Choo; Sang-Oh Yoon; Sang Gyun Kim; Philippe P Roux; John Blenis
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-27       Impact factor: 11.205

Review 3.  A new MAFia in cancer.

Authors:  Alain Eychène; Nathalie Rocques; Celio Pouponnot
Journal:  Nat Rev Cancer       Date:  2008-09       Impact factor: 60.716

4.  Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis.

Authors:  Umut Ozcan; Lale Ozcan; Erkan Yilmaz; Katrin Düvel; Mustafa Sahin; Brendan D Manning; Gökhan S Hotamisligil
Journal:  Mol Cell       Date:  2008-03-14       Impact factor: 17.970

5.  mTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation.

Authors:  Feng Hong; Michelle D Larrea; Cheryl Doughty; David J Kwiatkowski; Rachel Squillace; Joyce M Slingerland
Journal:  Mol Cell       Date:  2008-06-20       Impact factor: 17.970

6.  The PTEN-PI3K pathway: of feedbacks and cross-talks.

Authors:  A Carracedo; P P Pandolfi
Journal:  Oncogene       Date:  2008-09-18       Impact factor: 9.867

7.  mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1).

Authors:  Juan M García-Martínez; Dario R Alessi
Journal:  Biochem J       Date:  2008-12-15       Impact factor: 3.857

8.  Effects of aneuploidy on cellular physiology and cell division in haploid yeast.

Authors:  Eduardo M Torres; Tanya Sokolsky; Cheryl M Tucker; Leon Y Chan; Monica Boselli; Maitreya J Dunham; Angelika Amon
Journal:  Science       Date:  2007-08-17       Impact factor: 47.728

9.  Identification of primary MAFB target genes in multiple myeloma.

Authors:  Esther van Stralen; Marc van de Wetering; Luca Agnelli; Antonino Neri; Hans C Clevers; Bert J E G Bast
Journal:  Exp Hematol       Date:  2008-11-13       Impact factor: 3.084

10.  Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.

Authors:  Morris E Feldman; Beth Apsel; Aino Uotila; Robbie Loewith; Zachary A Knight; Davide Ruggero; Kevan M Shokat
Journal:  PLoS Biol       Date:  2009-02-10       Impact factor: 8.029

View more
  580 in total

Review 1.  Many multiple myelomas: making more of the molecular mayhem.

Authors:  Marta Chesi; P Leif Bergsagel
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2011

2.  Functional characterization of glycine N-methyltransferase and its interactive protein DEPDC6/DEPTOR in hepatocellular carcinoma.

Authors:  Chia-Hung Yen; Yao-Cheng Lu; Chung-Hsien Li; Cheng-Ming Lee; Chia-Yen Chen; Ming-Yuan Cheng; Shiu-Feng Huang; Kuen-Feng Chen; Ann-Lii Cheng; Li-Ying Liao; Yan-Hwa Wu Lee; Yi-Ming Arthur Chen
Journal:  Mol Med       Date:  2012-03-30       Impact factor: 6.354

Review 3.  Significance of SGK1 in the regulation of neuronal function.

Authors:  Florian Lang; Nathalie Strutz-Seebohm; Guiscard Seebohm; Undine E Lang
Journal:  J Physiol       Date:  2010-06-07       Impact factor: 5.182

Review 4.  Regulation of TOR by small GTPases.

Authors:  Raúl V Durán; Michael N Hall
Journal:  EMBO Rep       Date:  2012-02-01       Impact factor: 8.807

Review 5.  Rapamycin-resistant effector T-cell therapy.

Authors:  Daniel H Fowler
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

6.  Targeting PYK2 mediates microenvironment-specific cell death in multiple myeloma.

Authors:  M B Meads; B Fang; L Mathews; J Gemmer; L Nong; I Rosado-Lopez; T Nguyen; J E Ring; W Matsui; A R MacLeod; J A Pachter; L A Hazlehurst; J M Koomen; K H Shain
Journal:  Oncogene       Date:  2015-09-21       Impact factor: 9.867

7.  microRNA-181a downregulates deptor for TGFβ-induced glomerular mesangial cell hypertrophy and matrix protein expression.

Authors:  Soumya Maity; Amit Bera; Nandini Ghosh-Choudhury; Falguni Das; Balakuntalam S Kasinath; Goutam Ghosh Choudhury
Journal:  Exp Cell Res       Date:  2018-02-01       Impact factor: 3.905

8.  Gonadotropin releasing hormone activation of the mTORC2/Rictor complex regulates actin remodeling and ERK activity in LβT2 cells.

Authors:  Brian S Edwards; William J Isom; Amy M Navratil
Journal:  Mol Cell Endocrinol       Date:  2016-09-20       Impact factor: 4.102

9.  Inactivation of SAG/RBX2 E3 ubiquitin ligase suppresses KrasG12D-driven lung tumorigenesis.

Authors:  Hua Li; Mingjia Tan; Lijun Jia; Dongping Wei; Yongchao Zhao; Guoan Chen; Jie Xu; Lili Zhao; Dafydd Thomas; David G Beer; Yi Sun
Journal:  J Clin Invest       Date:  2014-01-16       Impact factor: 14.808

Review 10.  What is the impact of immunosuppressive treatment on the post-transplant renal osteopathy?

Authors:  Kristina Blaslov; Lea Katalinic; Petar Kes; Goce Spasovski; Ruzica Smalcelj; Nikolina Basic-Jukic
Journal:  Int Urol Nephrol       Date:  2013-11-12       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.